Prot #TPI-ALV-201: A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML and Exploratory Arms with Varying Levels

Project: Research project

Project Details

StatusActive
Effective start/end date10/24/1810/24/21

Funding

  • Tolero Pharmaceuticals, Inc. (Prot #TPI-ALV-201)